# MCL-1 inhibitor payloads

Source: https://onco.cc/terms/mcl1-inhibitor-payloads/  
OnCo record `mcl1-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads block another protein that can protect cancer cells from dying. Antibody delivery is being studied to direct that effect toward selected blood cancers.

## Summary

S227928 links the MCL-1 inhibitor S64315, also called MIK665, to a CD74-directed antibody. The primary ASH abstract reported intracellular payload release and target engagement in leukemia models. Single-agent activity was modest in the reported models, while combining the conjugate with the separate BCL-2 inhibitor venetoclax increased activity. This is an MCL-1 payload plus a separate drug, not a dual-payload construct. Preclinical results and a registered early trial do not establish clinical benefit or removal of the safety concerns associated with MCL-1 inhibition.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: S64315 payload; MIK665 payload; S227928 payload

## Notes

- The antibody binds CD74 on the cell surface; the payload acts on MCL-1 inside the cell. Approval of a different medicine linked to MCL1 does not establish approval of this conjugate.

## Sources

- Maragno et al., S227928 preclinical ASH abstract (2024): https://doi.org/10.1182/blood-2024-210048
- ClinicalTrials.gov: NCT06563804: https://clinicaltrials.gov/study/NCT06563804

## Connected records

- terms: [BCL-XL inhibitor payloads](https://onco.cc/terms/bcl-xl-inhibitor-payloads/), [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [MCL1](https://onco.cc/targets/mcl1/)

---
JSON: https://onco.cc/api/v1/entities/mcl1-inhibitor-payloads.json